Tags

Type your tag names separated by a space and hit enter

Mirabegron for male lower urinary tract symptoms.
Curr Urol Rep. 2013 Dec; 14(6):580-4.CU

Abstract

Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in men. Patients with BPH often present with a combination of obstructive and overactive bladder (OAB) symptoms. It is postulated that bladder outlet obstruction (BOO) from BPH results in concomitant OAB symptoms through ischemic induced variations in the response to neurotransmitters of both the detrusor and the urothelium. This altered response leads to the pathologic activation of the micturition reflex, generating sensory dysfunction and involuntary bladder contractions. Alpha-1 adrenoceptor antagonists (alpha-blockers) and 5-alpha reductase inhibitors (5-ARIs) are commonly used to treat the BOO caused by BPH. Anticholinergic agents are frequently used to treat concurrently OAB symptoms caused by the BOO. Unfortunately, anticholinergic medications demonstrate bothersome side effects and a theoretical risk of urinary retention. Basic science and clinical research has led to the development of a new class of pharmaceuticals for the treatment of overactive bladder with diminished risk of urinary retention and lacking many anticholinergic side effects. This novel compound, mirabegron (Mybertriq, Astellas Pharma US, Inc.), is a β₃-adrenoceptor agonist and represents a promising new class of oral agents designed for the treatment of OAB symptoms, with minimal effect on voiding.

Authors+Show Affiliations

Departamento de Urología, Hospital Universitario de la Universidad Autónoma de Nuevo León, Av. Madero Y Gonzalitos S/N Mitras Centro, C.P. 64460, Monterrey, Nuevo León, Mexico, osuarezfl@gmail.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23913200

Citation

Suarez, Oscar, et al. "Mirabegron for Male Lower Urinary Tract Symptoms." Current Urology Reports, vol. 14, no. 6, 2013, pp. 580-4.
Suarez O, Osborn D, Kaufman M, et al. Mirabegron for male lower urinary tract symptoms. Curr Urol Rep. 2013;14(6):580-4.
Suarez, O., Osborn, D., Kaufman, M., Reynolds, W. S., & Dmochowski, R. (2013). Mirabegron for male lower urinary tract symptoms. Current Urology Reports, 14(6), 580-4. https://doi.org/10.1007/s11934-013-0363-4
Suarez O, et al. Mirabegron for Male Lower Urinary Tract Symptoms. Curr Urol Rep. 2013;14(6):580-4. PubMed PMID: 23913200.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mirabegron for male lower urinary tract symptoms. AU - Suarez,Oscar, AU - Osborn,David, AU - Kaufman,Melissa, AU - Reynolds,W Stuart, AU - Dmochowski,Roger, PY - 2013/8/6/entrez PY - 2013/8/6/pubmed PY - 2014/6/15/medline SP - 580 EP - 4 JF - Current urology reports JO - Curr Urol Rep VL - 14 IS - 6 N2 - Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in men. Patients with BPH often present with a combination of obstructive and overactive bladder (OAB) symptoms. It is postulated that bladder outlet obstruction (BOO) from BPH results in concomitant OAB symptoms through ischemic induced variations in the response to neurotransmitters of both the detrusor and the urothelium. This altered response leads to the pathologic activation of the micturition reflex, generating sensory dysfunction and involuntary bladder contractions. Alpha-1 adrenoceptor antagonists (alpha-blockers) and 5-alpha reductase inhibitors (5-ARIs) are commonly used to treat the BOO caused by BPH. Anticholinergic agents are frequently used to treat concurrently OAB symptoms caused by the BOO. Unfortunately, anticholinergic medications demonstrate bothersome side effects and a theoretical risk of urinary retention. Basic science and clinical research has led to the development of a new class of pharmaceuticals for the treatment of overactive bladder with diminished risk of urinary retention and lacking many anticholinergic side effects. This novel compound, mirabegron (Mybertriq, Astellas Pharma US, Inc.), is a β₃-adrenoceptor agonist and represents a promising new class of oral agents designed for the treatment of OAB symptoms, with minimal effect on voiding. SN - 1534-6285 UR - https://www.unboundmedicine.com/medline/citation/23913200/Mirabegron_for_male_lower_urinary_tract_symptoms_ L2 - https://dx.doi.org/10.1007/s11934-013-0363-4 DB - PRIME DP - Unbound Medicine ER -